AIDS Vaccine's Low Efficacy Rate Makes Cmte. Skeptical About Phase III Potential
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA committee members express concern over vaccine's low CD8 cytotoxic T lymphocyte activity and lack of neutralizing antibody response in Phase II trial. Agency cites regulatory challenge associated with approving a vaccine that is not effective against U.S. sub-type of AIDS virus.
You may also be interested in...
Merck Research Labs Exec Joins VaxGen
Former Merck Research Labs Executive Director-Microbial Vaccine Research Kathrin Jansen, PhD, has been named senior VP-R&D and chief scientific officer at VaxGen, the company announced Oct. 19
Merck Research Labs Exec Joins VaxGen
Former Merck Research Labs Executive Director-Microbial Vaccine Research Kathrin Jansen, PhD, has been named senior VP-R&D and chief scientific officer at VaxGen, the company announced Oct. 19
AIDS Vaccine Efficacy May Not Transfer To U.S. Population, FDA Says
The U.S. Army is conducting a Phase III study in Thailand of a product that combines Sanofi-Aventis and VaxGen vaccines, briefing materials for Vaccines & Related Biological Products Advisory Committee’s Sept. 23 meeting state. However, FDA considers the trial to be a “proof of concept” study.